Empowering Venture Capital Associates

Aimee Raleigh is a principal at Atlas Venture where she works alongside stellar entrepreneurs to build companies focused on innovative therapies and exciting new biology. Aimee serves as a board director at Travin Bio and several stealth newcos. She is a board observer at Triveni Bio, Vima Therapeutics, and Remix Therapeutics. She was previously an observer at Kailera Therapeutics (NASDAQ: KLRA), Aiolos Bio (acquired by GSK) and Versanis Bio (acquired by Eli Lilly).
Prior to joining Atlas, Aimee was a life sciences consultant at L.E.K. Consulting. At L.E.K., she worked with pharmaceutical and biotechnology clients on strategy for early-stage therapies, including asset diligence, pipeline and indication prioritization, and commercial planning. Aimee received her PhD in bioengineering from the University of California, San Diego, where she was mentored by Dr. Robert Sah and Dr. Gary Firestein. Her doctoral work focused on modeling biophysical mechanisms of disrupted synovial joint lubricant homeostasis in post-traumatic osteoarthritis. Aimee received her BSE in biomedical engineering from Duke University, where she researched cell migration in response to chemokine gradients. Aimee now serves on the Duke Boston board.
What does it actually take to turn an idea into a biotech company?
Aimee Raleigh, PhD, Principal at Atlas Venture, joins Mike and Jen as she walks through how companies get built before they’re even companies. From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages.
We get into the pace of early-stage venture, how to juggle multiple opportunities, make decisions with imperfect data, figure out what’s worth leaning into, and more. Aimee discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
Listen and be prepared to walk away seeing early-stage ventures a little differently.
Mike is a partner in the San Francisco (SoMa) and San Diego offices of Wilson Sonsini Goodrich & Rosati. He has provided strategic intellectual property counseling to hundreds growth enterprises in the pharmaceutical and biotechnology industries, both venture-backed and public companies. His expertise includes patent strategy, prosecution, and diligence (both buy and sell side) for venture financings, public offerings, mergers and acquisitions.
Jennifer is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative startups grow into successful enterprises by providing counsel to the founders, management teams and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is a member of the National Venture Capital Association (NVCA) General Counsel Advisory Board and is a frequent speaker.